132P Neutrophil–lymphocyte ratio as an independent prognostic marker in chondrosarcoma: A single-center cohort
ESMO Rare Cancers · 2026-03 · 5 · 100338
DOI: 10.1016/j.esmorc.2026.100338 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von B. Pacaci und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Pacaci, B., Yildirim, B., Pacaci, I., Akagunduz, F., Köstek, O., & Demircan, N. (2026). 132P Neutrophil–lymphocyte ratio as an independent prognostic marker in chondrosarcoma: A single-center cohort. ESMO Rare Cancers, 5, 100338. https://doi.org/10.1016/j.esmorc.2026.100338
Vancouver
Pacaci B, Yildirim B, Pacaci I, Akagunduz F, Köstek O, Demircan N. 132P Neutrophil–lymphocyte ratio as an independent prognostic marker in chondrosarcoma: A single-center cohort. ESMO Rare Cancers. 2026;5:100338. doi:10.1016/j.esmorc.2026.100338
BibTeX
@article{Pacaci2026,
author = {Pacaci, B. and Yildirim, B. and Pacaci, I. and Akagunduz, F. and Köstek, O. and Demircan, N.C.},
title = {132P Neutrophil–lymphocyte ratio as an independent prognostic marker in chondrosarcoma: A single-center cohort},
journal = {ESMO Rare Cancers},
year = {2026},
volume = {5},
pages = {100338},
doi = {10.1016/j.esmorc.2026.100338}
}
EUVIMED